logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
after Q1 2019
Conatus Pharmaceuticals Inc
Results from Phase 2b trial of Emricasan (ENCORE-NF)
NASH fibrosis
after Q1 2019
BeyondSpring Inc.
Final data readout from phase 2/3 trial of Plinabulin ( Study 105)
Neutropenia
Q1 2019
Zosano Pharma Corporation
12-month safety data of long-term study of M207
Migraine
2019
OncoMed Pharmaceuticals Inc
Data from phase 1a single agent study of OMP-336B11
Solid tumors
2019
Calithera Biosciences Inc.
primary endpoint analysis from phase II trial of CB-839 in combination with Everolimus ( ENTRATA)
Late stage renal cell carcinoma
after Q1 2019
Dermira Inc.
Top line results Phase 2b dose-ranging study evaluating Lebrikizumab
Moderate-to-severe atopic dermatitis in adult patients
after Q1 2019
RHYTHM PHARMACEUTICALS, INC.
Initial data from phase III trial of Setmelanotide
POMC deficiency obesity
2019
Myovant Sciences Ltd
Data from 1st phase III trials of Relugolix (LIBERTY 1)
Heavy menstrual bleeding associated with uterine fibroids in Women
2019
Myovant Sciences Ltd
Data from 2nd phase III trial of Relugolix (LIBERTY 2)
Heavy menstrual bleeding associated with uterine fibroids in Women
2019
Myovant Sciences Ltd
Data from 1st phase III trial of Relugolix (SPIRIT 1)
Endometriosis-associated pain in Women
2019
Myovant Sciences Ltd
Data from 2nd phase III trial of Relugolix (SPIRIT 2)
Endometriosis-associated pain in Women
2019
Myovant Sciences Ltd
Data from phase III trial of Relugolix (HERO)
Advanced prostate cancer in Men
after Q1 2019
Atara Biotherapeutics, Inc.
First results from ATA188 Phase 1 study
Progressive multiple sclerosis (MS)
after Q1 2019
Syndax Pharma
Top line results from Phase 1b/2 clinical trial of entinostat in combination with BAVENCIO(ENCORE 603)
Ovarian cancer
Early 2019
Flex Pharma Inc.
Top-line results from phase II trial of FLX-787 (COMMEND)
Motor neuron disease
after Q1 2019
BioXcel Therapeutics, Inc.
Preliminary data from Phase 2 PoC clinical trial of BXCL701
tNEPC and Pancreatic Cancer
2019
Cidara Therapeutics, Inc.
Interim futility read-out from phase III pivotal clinical trial of Rezafungin(ReSPECT Prophylaxis)
Allogeneic bone marrow transplant
2019
VERU INC.
Data from phase II study of VERU-944
Hot flashes caused by prostate cancer hormonal therapies in men with advanced prostate cancer
2019
Edwards Lifesciences Corp.
Data from the PARTNER 3 main study of the SAPIEN 3 valve
Low-risk patients undergoing valve replacement for severe aortic stenosis
after Q1 2019
SOLIGENIX, INC.
Results from pivotal phase III study of SGX301
Cutaneous T-cell lymphoma
after Q1 2019
Celsion Corp.
Interim efficacy analysis from Phase III OPTIMA Study of ThermoDox
Primary liver cancer
after Q1 2019
Conatus Pharmaceuticals Inc
Top-line results from phase IIb clinical trial of Emricasan (ENCORE-NF)
NASH fibrosis
after Q1 2019
Minerva Neurosciences Inc
Topline results from phase 2b trial of MIN-117 (Study MIN-117C03)
Major depressive disorder
after Q1 2019
Palatin Technologies Inc.
Preliminary data from phase IIa trial of PL-3994
Heart Failure with Preserved Ejection Fraction (HF-pEF)